TF and neoplasm: Employing a twice-weekly dosing regimen for four weeks, a statistically significant reduction in tumor burden was observed only for those nanoparticles which contained (i) the anti-EWS-Fli1 siRNA and (ii) the Tf targeting ligand (Figure 9(a)).